Yabao Pharmaceutical Group Co (SHSE:600351) Beneish M-Score: -3.18 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600351 Yabao Pharmaceutical Group Co Ltd SHSE:600351
70 GF Score
Price ¥6.56
GF Value ¥5.53
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Yabao Pharmaceutical Group Co Beneish M-Score?

Yabao Pharmaceutical Group Co SHSE:600351 -3.53% 70 Beneish M-Score is -3.18 as of Jul. 18, 2026. GuruFocus rates SHSE:600351 with a GF Score™ of 70/100 and a GF Value™ of ¥5.53 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 911 Drug Manufacturers companies, Yabao Pharmaceutical Group Co ranks better than 87.27% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.18 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Yabao Pharmaceutical Group Co's Beneish M-Score or its related term are showing as below:

SHSE:600351' s Beneish M-Score Range Over the Past 10 Years
Min: -3.3   Med: -2.73   Max: -1.56
Current: -3.18

During the past 13 years, the highest Beneish M-Score of Yabao Pharmaceutical Group Co was -1.56. The lowest was -3.30. And the median was -2.73.


Yabao Pharmaceutical Group Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Yabao Pharmaceutical Group Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yabao Pharmaceutical Group Co Beneish M-Score Chart

Yabao Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.80 -2.78 -2.94 -2.81 -2.98

Yabao Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.42 -2.87 -3.16 -2.98 -3.18

SHSE:600351 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Yabao Pharmaceutical Group Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yabao Pharmaceutical Group Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Yabao Pharmaceutical Group Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Yabao Pharmaceutical Group Co's Beneish M-Score falls into.


SHSE:600351
70GF Score
Yabao Pharmaceutical Group Co Ltd SHSE:600351
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yabao Pharmaceutical Group Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Yabao Pharmaceutical Group Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8349+0.528 * 0.9613+0.404 * 0.8916+0.892 * 0.8688+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9387+4.679 * -0.0904-0.327 * 0.8657
=-3.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥382 Mil.
Revenue was 572.022 + 531.351 + 569.304 + 524.875 = ¥2,198 Mil.
Gross Profit was 304.569 + 285.442 + 292.01 + 273.546 = ¥1,156 Mil.
Total Current Assets was ¥1,604 Mil.
Total Assets was ¥3,279 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,033 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥382 Mil.
Total Current Liabilities was ¥410 Mil.
Long-Term Debt & Capital Lease Obligation was ¥36 Mil.
Net Income was 106.662 + 104.919 + 40.697 + 67.128 = ¥319 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 186.435 + 117.104 + 129.363 + 182.9 = ¥616 Mil.
Total Receivables was ¥527 Mil.
Revenue was 614.533 + 564.528 + 677.823 + 672.473 = ¥2,529 Mil.
Gross Profit was 325.277 + 290.303 + 314.173 + 348.834 = ¥1,279 Mil.
Total Current Assets was ¥1,614 Mil.
Total Assets was ¥3,569 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,172 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥468 Mil.
Total Current Liabilities was ¥559 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(381.976 / 2197.552) / (526.603 / 2529.357)
=0.173819 / 0.208196
=0.8349

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1278.587 / 2529.357) / (1155.567 / 2197.552)
=0.505499 / 0.525843
=0.9613

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1604.431 + 1032.592) / 3278.717) / (1 - (1613.88 + 1171.825) / 3569.135)
=0.195715 / 0.219501
=0.8916

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2197.552 / 2529.357
=0.8688

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 1171.825)) / (0 / (0 + 1032.592))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(382.026 / 2197.552) / (468.433 / 2529.357)
=0.173842 / 0.185198
=0.9387

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((36.18 + 409.771) / 3278.717) / ((1.88 + 558.893) / 3569.135)
=0.136014 / 0.157117
=0.8657

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(319.406 - 0 - 615.802) / 3278.717
=-0.0904

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Yabao Pharmaceutical Group Co has a M-score of -3.18 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.18 mean?
Yabao Pharmaceutical Group Co (SHSE:600351) has a Beneish M-Score of -3.18 as of Jul. 18, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Yabao Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Yabao Pharmaceutical Group Co ranks #116 out of 911 companies in the Drug Manufacturers industry, placing it in the top 12.7%.
Is Yabao Pharmaceutical Group Co's Beneish M-Score too high?
Yabao Pharmaceutical Group Co's current Beneish M-Score is -3.18. Based on the distribution chart, Yabao Pharmaceutical Group Co ranks #116 out of 911 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Yabao Pharmaceutical Group Co has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Yabao Pharmaceutical Group Co's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Yabao Pharmaceutical Group Co ranks #116 out of 911 companies for Beneish M-Score. This places Yabao Pharmaceutical Group Co in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Yabao Pharmaceutical Group Co and its competitors. Yabao Pharmaceutical Group Co's current Beneish M-Score is -3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yabao Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co (SHSE:600351) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥5.53, compared to a current price of ¥6.56 — trading 18.6% above its estimated fair value. The current Beneish M-Score is -3.18. Yabao Pharmaceutical Group Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Yabao Pharmaceutical Group Co (SHSE:600351), the current Beneish M-Score is -3.18 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Yabao Pharmaceutical Group Co (SHSE:600351) Overvalued in 2026?

Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co stock appears to be overvalued. The current stock price of ¥6.56 is trading 18.6% above its estimated GF Value™ of ¥5.53. GuruFocus considers Yabao Pharmaceutical Group Co to be Modestly Overvalued.

Key valuation signals for SHSE:600351:

  • Beneish M-Score: -3.18
  • GF Value™: ¥5.53 vs. price of ¥6.56 (18.6% above fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600351 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Yabao Pharmaceutical Group Co Business Description

Address No.43 Fumin Road, Ruicheng, Shanxi Province, Yuncheng, CHN, 044602
Yabao Pharmaceutical Group Co Ltd is engaged in the manufacture and operation of western and Chinese medicines, APIs, health care products, packing materials for medicine, and also engages in the planting and processing of medicinal herbs.
70GF Score

Get the complete analysis for SHSE:600351

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥6.56
Price
¥5.53
GF Value